Kodiak Sciences Inc.

KOD Healthcare Biotechnology

EPS
−1.94%
Free cash flow
−33.9%

Quarter to June 2026, against a year earlier

98.85 7.83 +8.60%
Market cap
$5.7B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Kodiak Sciences Inc. 8-K filed Jun 4, 2026

Period ended Jun 2, 2026 · Filed · accepted 5:22 PM ET · Document on sec.gov · Filing index

5.07 Submission of matters to a vote of security holders

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov